Cargando…
Development and acceptability testing of a decision aid for considering whether to reduce antipsychotics in individuals with stable schizophrenia
AIM: Continued antipsychotic treatment is the key to preventing relapse. Maintenance antipsychotic monotherapy and optimal dose use are recommended for individuals with stable schizophrenia because of their undesirable effects. Decision aids (DAs) are clinical conversation tools that facilitate shar...
Autores principales: | Aoki, Yumi, Takaesu, Yoshikazu, Matsui, Kentaro, Tokumasu, Takahiro, Tani, Hideaki, Takekita, Yoshiteru, Kanazawa, Tetsufumi, Kishimoto, Taishiro, Tarutani, Seiichiro, Hashimoto, Naoki, Takeuchi, Hiroyoshi, Mishima, Kazuo, Inada, Ken |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496039/ https://www.ncbi.nlm.nih.gov/pubmed/37452456 http://dx.doi.org/10.1002/npr2.12366 |
Ejemplares similares
-
Development and acceptability of a decision aid for anxiety disorder considering discontinuation of benzodiazepine anxiolytic
por: Aoki, Yumi, et al.
Publicado: (2023) -
Association between Medication Adherence and Duration of Outpatient Treatment in Patients with Schizophrenia
por: Tarutani, Seiichiro, et al.
Publicado: (2016) -
Development and acceptability of a decision aid for major depressive disorder considering discontinuation of antidepressant treatment after remission
por: Aoki, Yumi, et al.
Publicado: (2022) -
Rehospitalization Risk of Receptor-Affinity Profile in Antipsychotic Drug Treatment: A Propensity Score Matching Analysis Using a Japanese Employment-Based Health Insurance Database
por: Takekita, Yoshiteru, et al.
Publicado: (2020) -
Development and acceptability of a decision aid for chronic insomnia considering discontinuation of benzodiazepine hypnotics
por: Aoki, Yumi, et al.
Publicado: (2021)